PAVmed (PAVM) CEO Aklog reports 5.1% stake and 350,000 restricted shares

Rhea-AI Filing Summary

PAVmed Inc. Chairman and CEO Lishan Aklog, M.D. filed a Schedule 13D reporting beneficial ownership of 369,068 shares of PAVmed common stock, representing 5.1% of the 7,272,739 shares outstanding as of April 2, 2026. The issuer granted him 350,000 shares of restricted common stock under its Seventh Amended and Restated Long-Term Incentive Equity Plan in consideration of services as Chairman and CEO. These restricted shares, along with existing holdings, options and small indirect interests through entities and family members, make up his reported beneficial ownership. The filing states the shares are held for investment purposes and that, apart from routine investment activity consistent with his roles, he has no current plans for major corporate changes.

Key Figures

Beneficial ownership: 369,068 shares Ownership percentage: 5.1% Shares outstanding: 7,272,739 shares +5 more

8 metrics

Beneficial ownership 369,068 shares PAVmed common stock beneficially owned by Lishan Aklog

Ownership percentage 5.1% Percent of PAVmed common stock class represented by 369,068 shares

Shares outstanding 7,272,739 shares PAVmed common stock outstanding as of April 2, 2026

New restricted stock grant 350,000 shares Restricted PAVmed common stock granted April 2, 2026

Options exercisable 1,495 shares PAVmed common stock issuable upon exercise of options held by Aklog

Option exercise prices $2,250.00, $904.50, $715.50 Exercise prices for options on 618, 433 and 444 shares

Option expirations 2026, 2028, 2032 Option expiry dates: April 28, 2026; Feb 14, 2028; Feb 18, 2032

Restricted stock vesting May 20, 2026/2028/2029 Vesting dates for 555, 333, 5,000 and 350,000 restricted shares

Key Terms

Schedule 13D, beneficially owns, restricted Common Stock, Seventh Amended and Restated Long-Term Incentive Equity Plan, +2 more

6 terms

Schedule 13D regulatory

"This is filed by Lishan Aklog, M.D. ("Dr. Aklog" or the "Reporting Person") with respect to ownership of the common stock"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

beneficially owns financial

"Dr. Aklog beneficially owns 369,068 shares of Common Stock, comprised of (i) 357,614 shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

restricted Common Stock financial

"The Issuer granted 350,000 shares of restricted Common Stock to Dr. Aklog pursuant to its Seventh Amended and Restated Long-Term Incentive Equity Plan"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

Seventh Amended and Restated Long-Term Incentive Equity Plan financial

"pursuant to its Seventh Amended and Restated Long-Term Incentive Equity Plan, in consideration of services rendered"

sole power to vote and dispose financial

"Dr. Aklog has sole power to vote and dispose of 369,023 shares"

dispositive power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power 369,023.00 8 | Shared Voting Power 45.00 9 | Sole Dispositive Power 369,023.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

PAVmed Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

(CUSIP Number)

Lishan Aklog
360 MADISON AVENUE, 25TH FLOOR
NEW YORK, NY, 10017
(917) 813-1828

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP No.

1

Name of reporting person

Aklog Lishan

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 369,023.00
8	Shared Voting Power 45.00
9	Sole Dispositive Power 369,023.00
10	Shared Dispositive Power 45.00

11

Aggregate amount beneficially owned by each reporting person

369,068.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: PAVmed Inc.
(c)	Address of Issuer's Principal Executive Offices: 360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NEW YORK , 10017.
Item 1 Comment: This Schedule 13D is filed by Lishan Aklog, M.D. ("Dr. Aklog" or the "Reporting Person") with respect to ownership of the common stock, par value $0.001 per share ("Common Stock"), of PAVmed Inc., a Delaware corporation (the "Issuer"). The percentage of beneficial ownership reflected in this Schedule 13D is based upon 7,272,739 shares of Common Stock outstanding as of April 2, 2026.
Item 2.	Identity and Background
(a)	The name of the Reporting Person is Lishan Aklog, M.D.
(b)	Dr. Aklog's business address is 360 Madison Avenue, 25th Floor, New York, New York 10017.
(c)	Dr. Aklog is the Chairman and Chief Executive Officer of the Issuer and is the Chairman and Chief Executive Officer of Lucid Diagnostics Inc., the Issuer's subsidiary.
(d)	Dr. Aklog has not, during the past five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	Dr. Aklog has not, during the past five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	Dr. Aklog is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	The Issuer granted 350,000 shares of restricted Common Stock to Dr. Aklog pursuant to its Seventh Amended and Restated Long-Term Incentive Equity Plan, in consideration of services rendered and to be rendered to the Issuer by Dr. Aklog in his role as Chairman and Chief Executive Officer of the Issuer.
Item 4.	Purpose of Transaction
	Dr. Aklog acquired beneficial ownership of the shares of Common Stock described in this Schedule 13D for investment purposes. Dr. Aklog may from time to time acquire beneficial ownership of additional securities for investment purposes, or dispose of securities, in the open market or in private transactions, including upon exercise of options described below and subject to the restricted stock agreements described below. At the date of this Schedule 13D, except as set forth in this Schedule 13D, and as consistent with Dr. Aklog's position as Chairman and Chief Executive Officer of the Issuer, Dr. Aklog has no plans or proposals which would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of the board of directors or management of the Issuer; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or (j) Any action similar to any of those actions enumerated above.
Item 5.	Interest in Securities of the Issuer
(a)	Dr. Aklog beneficially owns 369,068 shares of Common Stock, comprised of (i) 357,614 shares of Common Stock held by Dr. Aklog, (ii) 45 shares of Common Stock held by HCFP/AG LLC, which Dr. Aklog may be deemed to beneficially own because he serves as a co-manager of such entity, (iii) 9,904 shares of Common Stock held by Pavilion Venture Partners LLC, which Dr. Aklog may be deemed to beneficially own because he serves as manager of such entity, (iv) 10 shares of Common Stock held by Dr. Aklog's children, and (v) 1,495 shares of Common Stock issuable upon the exercise of the options held by Dr. Aklog.
(b)	Dr. Aklog has sole power to vote and dispose of 369,023 shares, comprised of the shares held by Dr. Aklog, the shares held by Pavilion Venture Partners LLC, the shares held by Dr. Aklog's children, and the shares subject to options held by Dr. Aklog. Dr. Aklog has shared power to vote and dispose of 45 shares, comprised of the shares held by HCFP/AG LLC.
(c)	On April 2, 2026, the Issuer granted Dr. Aklog 350,000 shares of restricted Common Stock, pursuant to the Issuer's Seventh Amended and Restated Long-Term Incentive Equity Plan.
(d)	HCFP/AG LLC, Pavilion Venture Partners LLC and Dr. Aklog's children have the right to receive dividends from, and the proceeds from the sale of, certain of the shares of Common Stock, as described above.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Dr. Aklog is party to option agreements and restricted stock agreements with the Issuer. The option agreements provide for Dr. Aklog to purchase 618, 433, and 444 shares of Common Stock, respectively, at exercise prices of $2,250.00, $904.50, and $715.50, respectively, and expire on April 28, 2026, February 14, 2028 and February 18, 2032, respectively. The restricted stock agreements cover 555, 333, 5,000 and 350,000 shares of restricted stock, respectively, granted to Dr. Aklog on May 1, 2020, April 1, 2021, September 30, 2025 and April 2, 2026, respectively, with single vesting dates of May 20, 2026, May 20, 2026, May 20, 2028 and May 20, 2029, respectively.
Item 7.	Material to be Filed as Exhibits.
	99.1 Form of option agreement (http://www.sec.gov/Archives/edgar/data/1624326/000149315223007481/ex10-12.htm). 99.2 Form of restricted stock agreement (filed herewith).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aklog Lishan

Signature:	/s/ Lishan Aklog, M.D.
Name/Title:	Lishan Aklog, M.D.
Date:	04/09/2026

FAQ

What percentage of PAVmed (PAVM) shares does Lishan Aklog report owning?

Lishan Aklog, M.D. reports beneficial ownership of 369,068 PAVmed common shares, representing 5.1% of the 7,272,739 shares outstanding as of April 2, 2026. This total includes direct, indirect and option-based holdings described in the filing.

How many PAVmed (PAVM) restricted shares were granted to Lishan Aklog?

PAVmed granted Lishan Aklog 350,000 shares of restricted common stock on April 2, 2026. The grant was made under the company’s Seventh Amended and Restated Long-Term Incentive Equity Plan as consideration for services in his role as Chairman and Chief Executive Officer.

What is the nature of Lishan Aklog’s investment intent in PAVmed (PAVM) shares?

The filing states that Lishan Aklog acquired beneficial ownership of PAVmed common stock for investment purposes. It notes he may buy or sell additional securities over time, but currently has no specific plans for major corporate transactions or structural changes involving the company.

What option agreements does Lishan Aklog hold for PAVmed (PAVM) stock?

Lishan Aklog holds options to purchase 618, 433 and 444 PAVmed common shares at exercise prices of $2,250.00, $904.50 and $715.50, expiring April 28, 2026, February 14, 2028 and February 18, 2032. A portion of his beneficial ownership includes shares issuable upon option exercise.

When do Lishan Aklog’s PAVmed (PAVM) restricted stock awards vest?

Restricted stock agreements cover 555, 333, 5,000 and 350,000 PAVmed shares granted on May 1, 2020, April 1, 2021, September 30, 2025 and April 2, 2026. These awards have single vesting dates of May 20, 2026, May 20, 2026, May 20, 2028 and May 20, 2029, respectively.

Does the PAVmed (PAVM) Schedule 13D indicate plans for major corporate changes?

The Schedule 13D states that, apart from investment-related activity, Lishan Aklog currently has no plans or proposals for major actions such as mergers, significant asset sales, changes to the board or management structure, or other material changes to PAVmed’s business or capital structure.